Susan Altschuller - 30 May 2024 Form 4/A Insider Report for Mural Oncology plc (MURA)

Reporting relationship: Director
Issuer ticker: MURA
Reported as of: 30 May 2024
Net transaction value: $0
SEC form: 4/A
Accepted by SEC: 05 Jun 2024, 16:08:16 UTC
Original report date: 03 Jun 2024
Prior SEC filing: 23 Jan 2024
Next SEC filing: 05 Aug 2024
Source filing: View source filing
Reporting owner signature: /s/ Maiken Keson-Brookes, attorney-in-fact for Susan Altschuller

Key filing fact

Susan Altschuller filed Form 4/A for Mural Oncology plc (MURA) on 05 Jun 2024.

Key facts

This page summarizes Susan Altschuller's Form 4/A filing for Mural Oncology plc (MURA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 05 Jun 2024, 16:08.

Change

Previous filing in this sequence was filed on 23 Jan 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MURA transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +8,462
Change %
Price: $0.000000
Shares after: 8,462
Date: 30 May 2024
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 8,462
Exercise price: $3.35
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

This option was granted on May 30, 2024. This option will vest in full upon the earlier of (i) the first anniversary of the date of the grant or (ii) the date of the next Annual Meeting, subject to the reporting person's continued service with the Issuer.

Footnote F2

This amendment to Form 4 is being filed solely to correct the price of the derivative security, which was previously reported as being $3.35 due to a scrivener's error.